Trials & R&D · first seen 6h ago, updated 6h ago

Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil

1 outlet Roche

Roche’s Genentech is paying Earendil Labs $55 million upfront to discover and develop multiple bispecific antibodies. The deal, which focuses on oncology, includes milestones that could take the deal's value above $1.5 billion.

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

Fierce Biotech - Biotech 6h ago
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil